Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

LTS Lohmann Therapie-Systeme Company Profile - aVenture Research

LTS Lohmann Therapie-Systeme

LTS Lohmann Therapie-Systeme

LTS Lohmann: A German-based therapeutics company specializing in transdermal systems and oral thin films.

: 1k
: dievini Hopp Biotech Holding

Andernach, Rhineland-Palatinate, DE🇩🇪Germany

Founded in Andernach, Germany, LTS Lohmann Therapie-Systeme AG is a pioneering therapeutics company dedicated to developing and manufacturing transdermal systems and oral thin films. The company's core mission is to advance drug delivery technologies to improve patient outcomes globally. LTS Lohmann offers comprehensive services from research and development of new formulations to production, packaging, and testing, serving a diverse range of customers worldwide.

Notable affiliated individuals and investors include leading pharmaceutical experts and strategic partners in the healthcare industry. LTS Lohmann has achieved significant milestones in drug delivery innovation, contributing to enhanced therapeutic efficacy and patient compliance. The company's impact is evident in its widespread adoption of transdermal systems and oral thin films, setting new standards in the global therapeutics market.

M & A Snapshot

dievini Hopp Biotech Holding
Acquired LTS Lohmann Therapie-Systeme
Nov 5, 2014

Quick Facts

When was LTS Lohmann Therapie-Systeme's last funding round?

LTS Lohmann Therapie-Systeme's most recent funding round was for $4.3M (USD) in December 2023.

How much disclosed funding has LTS Lohmann Therapie-Systeme raised?

As of Dec 19, 2023, LTS Lohmann Therapie-Systeme has disclosed funding of $5.5M (USD).

Classification

Industry: Hardware

Ownership

Public

Technology

Biotech

Geographic Exposure

Global

Revenue: Recurring
Software
Customer: Enterprise
Main Product: Drug Delivery
Pharmaceuticals

Tags: Pharmaceutical

Also Known As: LTS LOHMANN Therapie-Systeme AG.

Headquarters: 2 Lohmannstraße
Andernach, Rhineland-Palatinate, 56626
DE

NAICS: 320000ManufacturingEdition: 2022
325Chemical ManufacturingEdition: 2022
3254Pharmaceutical and Medicine ManufacturingEdition: 2022
32541Pharmaceutical and Medicine ManufacturingEdition: 2022
325412Pharmaceutical Preparation ManufacturingEdition: 2022
SIC: 28Chemicals And Allied ProductsEdition: 1987
283DrugsEdition: 1987
2834Pharmaceutical PreparationsEdition: 1987
ISIC: 4649Wholesale of other household goodsEdition: Rev.4
7210Research and experimental development on natural sciences and engineeringEdition: Rev.4
Industry: Pharmaceutical Companies
Chemical Companies

Show 2 more industry codes

SIC: 289Miscellaneous Chemical ProductsEdition: 1987
2899Chemicals And Chemical Preparations, Not Elsewhere ClassifiedEdition: 1987

Similar Companies

Aquestive Therapeutics

aquestive.com

Novel Therapeutic Technologies

ntt-inc.com

Alltranz

alltranz.com.au

Hera Health Solutions

NovaDel Pharma

Lyndra

lyndra.com

Talima Therapeutics

talima.com

TesoRx Pharma

tesorx.com

LTZ Therapeutics

Lumos Pharma

lumos-pharma.com

Transport Pharmaceuticals

Lonza

lonza.com

Knight Therapeutics

knighttx.com

Theron Pharmaceuticals

Luma Therapeutics

LQ3 Pharmaceuticals

Receptor Life Sciences

receptorlife.com

Logical Therapeutics

Lyra Therapeutics

Mechano-Therapeutics